Cargando…

Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients

Immunomodulation contributes to the antitumor efficacy of the fractionated radiation therapy (RT). Here, we describe immune effects of RT with concurrent systemic cisplatin or cetuximab treatment of patients with stage III-IV head and neck squamous cell carcinoma (HNSCC). Using longitudinally collec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampath, Sagus, Won, Haejung, Massarelli, Erminia, Li, Min, Frankel, Paul, Vora, Nayana, Vora, Lalit, Maghami, Ellie, Kortylewski, Marcin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834279/ https://www.ncbi.nlm.nih.gov/pubmed/29541413 http://dx.doi.org/10.18632/oncotarget.24397

Ejemplares similares

An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report
por: Pharaon, Rebecca R., et al.
Publicado: (2022)

Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
por: Juarez-Vignon Whaley, Juan Jose, et al.
Publicado: (2023)

Prognostic Impact of Primary Tumor Extent and Postoperative Radiation Facility Location in Major Salivary Gland Malignancies
por: Ladbury, Colton, et al.
Publicado: (2022)

Cutaneous Angiosarcoma of Head and Neck
por: Vora, Rita, et al.
Publicado: (2014)

STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
por: Su, Yu-Lin, et al.
Publicado: (2018)

Cell-selective oligonucleotide STAT3 inhibitor for immunotherapy of human acute myeloid leukemia
por: Zhang, Qifang, et al.
Publicado: (2015)

Precision medicine and actionable alterations in lung cancer: A single institution experience
por: Mambetsariev, Isa, et al.
Publicado: (2020)

Hypoxia promotes the tolerogenic phenotype of plasmacytoid dendritic cells in head and neck squamous cell carcinoma
por: Fan, Cui, et al.
Publicado: (2021)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation
por: Ochando, Jordi, et al.
Publicado: (2019)

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
por: Kortylewski, Marcin, et al.
Publicado: (2014)

Targeted TLR9-activation/STAT3-blocking abrogates immunosuppressive functions of myeloid-derived suppressor cells from late-stage prostate cancer patients
por: Md Sakib Hossain, Dewan, et al.
Publicado: (2014)

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors
por: Zhao, Xingli, et al.
Publicado: (2018)

An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.
por: Vora, A. R., et al.
Publicado: (1997)

Editorial: Roles of Tumor-Recruited Myeloid Cells in Immune Evasion in Cancer
por: Kusmartsev, Sergei, et al.
Publicado: (2021)

Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies
por: Suuring, Maaike, et al.
Publicado: (2021)

Inflammatory and tolerogenic myeloid cells determine outcome following human allergen challenge
por: Voskamp, Astrid L., et al.
Publicado: (2023)

The Induction of APC with a Distinct Tolerogenic Phenotype via Contact-Dependent STAT3 Activation
por: Gur-Wahnon, Devorah, et al.
Publicado: (2009)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
por: Pfister, David G., et al.
Publicado: (2022)

HLA-G Expression on Blasts and Tolerogenic Cells in Patients Affected by Acute Myeloid Leukemia
por: Locafaro, Grazia, et al.
Publicado: (2014)

Correction: Inflammatory and tolerogenic myeloid cells determine outcome following human allergen challenge
por: Voskamp, Astrid L., et al.
Publicado: (2023)

Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities
por: Huang, Samantha, et al.
Publicado: (2022)

Tolerogenic therapies in transplantation
por: Page, Eugenia K., et al.
Publicado: (2012)

Radiation-induced neuropathies in head and neck cancer: prevention and treatment modalities
por: Azzam, Patrick, et al.
Publicado: (2020)

Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies
por: Frankel, Paul H., et al.
Publicado: (2020)

Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer
por: Cubillos-Ruiz, Juan R., et al.
Publicado: (2017)

IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
por: Wang, Lin, et al.
Publicado: (2009)

Intraoperative Radiation Therapy: A Promising Treatment Modality in Head and Neck Cancer
por: Hilal, Lara, et al.
Publicado: (2017)

Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer
por: Argiris, Athanassios, et al.
Publicado: (2019)

Comparison of Clinical Examination and Various Imaging Modalities in the Diagnosis of Head and Neck Cancer
por: Schneider, Uwe, et al.
Publicado: (2021)

Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors
por: Lee, Heehyoung, et al.
Publicado: (2010)

Tolerogenic vaccines for Multiple Sclerosis
por: Mannie, Mark D., et al.
Publicado: (2013)

Tolerogenic citrullinated peptide for arthritis
por: Gertel, Smadar, et al.
Publicado: (2015)

Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs
por: Riquelme, Paloma, et al.
Publicado: (2012)

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
por: Pal, Sumanta K., et al.
Publicado: (2019)

Immunotherapy as a treatment modality for mucosal melanoma of the head and neck: A systematic review
por: Wehbe, Jad, et al.
Publicado: (2022)

Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
por: Li, Rui, et al.
Publicado: (2013)

SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer
por: Zhou, Z, et al.
Publicado: (2016)

Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer
por: Peyser, Noah D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6iv4rc36hf5o6fe0mj82lp21ho